search
Back to results

Efficacy and Safety of Eplivanserin 5mg/Day on Sleep Maintenance Insomnia (EPOCH)

Primary Purpose

Sleep Initiation and Maintenance Disorders, Insomnia

Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
eplivanserin (SR46349)
placebo
Sponsored by
Sanofi
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Sleep Initiation and Maintenance Disorders focused on measuring Primary Insomnia, Sleep Maintenance Insomnia, Awakening

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Diagnosis of primary insomnia based on Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria for at least one month preceding the study visit. Disturbance of sleep maintenance: Based on patient' s information: Patient has spent at least 6.5 hours and not more than 9.0 hours, in bed, each night, over the preceding two weeks, Patient must complain of at least one hour of wakefulness after sleep onset for at least 3 nights per week over the preceding month, Patient must report impact on daytime functioning associated with sleep maintenance insomnia Inclusion will be based on the nocturnal polysomnography (NPSG) recordings performed at the sleep laboratory during the two screening nights. Exclusion Criteria: Females who are lactating or who are pregnant, or of childbearing potential not using an acceptable form of contraception Patients presenting with acute or chronic pain resulting in insomnia Patients with current psychiatric disturbances Body mass index > 32 Evidence of any clinically significant, severe or unstable, acute or chronically progressive medical or surgical disorder, or any condition that may interfere with the absorption, metabolism, distribution or excretion of the study drug, or may affect patient safety Clinically significant and abnormal electrocardiogram (ECG) (including QTc B > 500ms), A positive test for hepatitis B (hepatitis B surface [HBs] antigens) or C (hepatitis C virus [HCV] antibodies) Positive qualitative urine drug screen at screening Consumption of xanthine-containing beverages (i.e. tea, coffee, or cola) comprising usually more than 5 cups or glasses per day Use of any over-the-counter or prescription sleep medication, or of any substance with psychotropic effects or properties known to affect sleep/wake, within one week or five half-lives (whichever is longer), prior to screening Night shift workers, and individuals who nap 3 or more times per week over the preceding month Based on medical history and/or NPSG: primary hypersomnia narcolepsy breathing-related sleep disorder (apnea-hypopnea index > 10/hour of sleep) circadian rhythm sleep disorder parasomnia (e.g. somnambulism)

Sites / Locations

  • Sanofi-Aventis
  • Sanofi-Aventis
  • Sanofi-Aventis

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

1

2

Arm Description

5 mg/day

Outcomes

Primary Outcome Measures

Change from baseline of night polysomnography Wake Time After Sleep Onset (PSG WASO)

Secondary Outcome Measures

Change from baseline in general productivity domain of the FOSQ (Functional Outcome of Sleep Questionnaire)
Change from baseline in patient reported wake after sleep onset (pr-WASO)

Full Information

First Posted
March 28, 2006
Last Updated
November 29, 2010
Sponsor
Sanofi
search

1. Study Identification

Unique Protocol Identification Number
NCT00308503
Brief Title
Efficacy and Safety of Eplivanserin 5mg/Day on Sleep Maintenance Insomnia
Acronym
EPOCH
Official Title
Efficacy and Safety of Eplivanserin 5mg/Day on Sleep Maintenance Insomnia: A 6 Week, Multicenter, Randomized, Double -Blind, Placebo-controlled Study
Study Type
Interventional

2. Study Status

Record Verification Date
November 2010
Overall Recruitment Status
Completed
Study Start Date
February 2006 (undefined)
Primary Completion Date
August 2007 (Actual)
Study Completion Date
August 2007 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Sanofi

4. Oversight

5. Study Description

Brief Summary
The aim of the study is to confirm the efficacy of eplivanserin 5mg/day on sleep maintenance of patients with primary insomnia using night polysomnography recordings over a 6-week treatment period corresponding to a stabilization of improvement of sleep.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Sleep Initiation and Maintenance Disorders, Insomnia
Keywords
Primary Insomnia, Sleep Maintenance Insomnia, Awakening

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
608 (Actual)

8. Arms, Groups, and Interventions

Arm Title
1
Arm Type
Experimental
Arm Description
5 mg/day
Arm Title
2
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
eplivanserin (SR46349)
Intervention Description
oral administration
Intervention Type
Drug
Intervention Name(s)
placebo
Intervention Description
oral administration
Primary Outcome Measure Information:
Title
Change from baseline of night polysomnography Wake Time After Sleep Onset (PSG WASO)
Time Frame
week 6
Secondary Outcome Measure Information:
Title
Change from baseline in general productivity domain of the FOSQ (Functional Outcome of Sleep Questionnaire)
Time Frame
week 6
Title
Change from baseline in patient reported wake after sleep onset (pr-WASO)
Time Frame
week 6

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Diagnosis of primary insomnia based on Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria for at least one month preceding the study visit. Disturbance of sleep maintenance: Based on patient' s information: Patient has spent at least 6.5 hours and not more than 9.0 hours, in bed, each night, over the preceding two weeks, Patient must complain of at least one hour of wakefulness after sleep onset for at least 3 nights per week over the preceding month, Patient must report impact on daytime functioning associated with sleep maintenance insomnia Inclusion will be based on the nocturnal polysomnography (NPSG) recordings performed at the sleep laboratory during the two screening nights. Exclusion Criteria: Females who are lactating or who are pregnant, or of childbearing potential not using an acceptable form of contraception Patients presenting with acute or chronic pain resulting in insomnia Patients with current psychiatric disturbances Body mass index > 32 Evidence of any clinically significant, severe or unstable, acute or chronically progressive medical or surgical disorder, or any condition that may interfere with the absorption, metabolism, distribution or excretion of the study drug, or may affect patient safety Clinically significant and abnormal electrocardiogram (ECG) (including QTc B > 500ms), A positive test for hepatitis B (hepatitis B surface [HBs] antigens) or C (hepatitis C virus [HCV] antibodies) Positive qualitative urine drug screen at screening Consumption of xanthine-containing beverages (i.e. tea, coffee, or cola) comprising usually more than 5 cups or glasses per day Use of any over-the-counter or prescription sleep medication, or of any substance with psychotropic effects or properties known to affect sleep/wake, within one week or five half-lives (whichever is longer), prior to screening Night shift workers, and individuals who nap 3 or more times per week over the preceding month Based on medical history and/or NPSG: primary hypersomnia narcolepsy breathing-related sleep disorder (apnea-hypopnea index > 10/hour of sleep) circadian rhythm sleep disorder parasomnia (e.g. somnambulism)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
ICD CSD
Organizational Affiliation
Sanofi
Official's Role
Study Director
Facility Information:
Facility Name
Sanofi-Aventis
City
Bridgewater
State/Province
New York
ZIP/Postal Code
08807
Country
United States
Facility Name
Sanofi-Aventis
City
Macquarie Park
State/Province
New South Wales
Country
Australia
Facility Name
Sanofi-Aventis
City
Laval
Country
Canada

12. IPD Sharing Statement

Learn more about this trial

Efficacy and Safety of Eplivanserin 5mg/Day on Sleep Maintenance Insomnia

We'll reach out to this number within 24 hrs